SCHEMBL7529957

SCHEMBL7529957

CCCCC=NNC(=O)c1[nH]c2ccccc2c1-c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.57
ALDH1A1 P00352 12/20 0.50
MAPT P10636 10/20 0.50
KDM4E B2RXH2 8/20 0.50
LMNA P02545 6/20 0.50
HPGD P15428 3/20 0.50
TDP1 Q9NUW8 2/20 0.50
PAX8 Q06710 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MEN1 O00255 7/20 0.48
KMT2A Q03164 7/20 0.48
CRHBP P24387 1/20 0.48
CRHR2 Q13324 1/20 0.48
MAP2 P11137 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.46
RAB9A P51151 1/20 0.46
TP53 P04637 1/20 0.46
POLB P06746 1/20 0.46
TUBB4A P04350 2/20 0.44
TUBB P07437 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7566792 1.00 GAA (0.57) GAAALDH1A1MAPTKDM4ELMNA
SCHEMBL7565744 0.93 GAA (0.60) GAAALDH1A1MAPTKDM4ELMNA
SCHEMBL7565738 0.93 GAA (0.60) GAAALDH1A1MAPTKDM4ELMNA
SCHEMBL7567200 0.79 MAPT (0.75) GAAALDH1A1MAPTKDM4ELMNA
SCHEMBL7567198 0.79 MAPT (0.75) GAAALDH1A1MAPTKDM4ELMNA
SCHEMBL9212419 0.77 GAA (0.62) GAAALDH1A1KDM4EHPGDMAP2
SCHEMBL7560583 0.76 RAB9A (0.60) GAAALDH1A1MAPTKDM4ELMNA
SCHEMBL7560582 0.76 RAB9A (0.60) GAAALDH1A1MAPTKDM4ELMNA
SCHEMBL7560462 0.76 GAA (0.55) GAAALDH1A1MAPTKDM4ELMNA
SCHEMBL7565507 0.76 MAPT (0.63) GAAALDH1A1MAPTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 GAA 3668/4885ALDH1A1 98/4885MAPT 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.